Informations générales (source: ClinicalTrials.gov)
Study of Ion Transport From Nasal Epithelial Cells Collected by Brushing (CCBN) in the Diagnosis of Atypical Forms of Cystic Fibrosis (MUCO-BROCC)
Interventional
N/A
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
mars 2015
septembre 2018
29 juin 2024
The diagnosis of CF is currently based on the discovery of two CFTR gene mutations and /
or a positive sweat test (> 60mmol / l). A significant number of patients with atypical
cystic fibrosis (chronic sino-pulmonary disease with a single mutation in the CFTR gene
and / or a test of the intermediate sweat between 30 and 60 mmol / l) undetected by these
techniques are behind specialized care while irreversible lung damage is already existed.
Currently, the measurement of nasal potential difference in vivo (DPN), which evaluates
the transportation of chlorine in the nasal epithelium with an electrode, is proposed for
the diagnosis of atypical forms. However DPN dependent nasal local conditions when
analysing do not always offer the possibility of concluding the diagnosis of cystic
fibrosis. It is necessary to develop new and more reliable diagnostic tests for the
detection of cases of atypical cystic fibrosis. The authors propose to develop a new
diagnostic technique based on the study of bioelectric properties of a preparation of
nasal cells of the subject obtained by brushing and placed in primary culture (CCBN).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- For patients with cystic fibrosis and those with atypical form:
• Inclusion at least 30 days after a general or local infection of the upper airways
- For controls:
• No history or Sino-pulmonary pathology and negative identification of mutations in
the CFTR gene
- For all subjects involved in research:
- Information and obtaining informed consent of the subjects.
- Age ≥ 18 years
- affiliation to a social security scheme or of such a regime
- For patients with cystic fibrosis and those with atypical form:
• Inclusion at least 30 days after a general or local infection of the upper airways
- For controls:
• No history or Sino-pulmonary pathology and negative identification of mutations in
the CFTR gene
- For all subjects involved in research:
- Information and obtaining informed consent of the subjects.
- Age ≥ 18 years
- affiliation to a social security scheme or of such a regime
- For all participants :
- Taking a per os corticoids or topical corticosteroid treatment in the nose in
the month preceding the nasal brushing or measurement of nasal potential
difference
- ORL surgical history of under 2 months
- cauterization of the inferior turbinate of under 2 months
- Hypersensitivity to local anesthetics of the amide (such as lidocaine) or with
one of the components, including methyl parahydroxybenzoate contained in the
excipient.
- Porphyria.
- Epilepsy not controlled by treatment.